The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Burden and characteristics of COVID-19 in the United States during 2020
Open accessPublished version of a preprint
Abstract
The COVID-19 pandemic disrupted health systems and economies throughout the world during 2020 and was particularly devastating for the United States, which experienced the highest numbers of reported cases and deaths during 2020 1-3. Many of the epidemiological features responsible for observed rates of morbidity and mortality have been reported 4-8; however, the overall burden and characteristics of COVID-19 in the United States have not been comprehensively quantified. Here we use a data-driven model-inference approach to simulate the pandemic at county-scale in the United States during 2020 and estimate critical, time-varying epidemiological properties underpinning the dynamics of the virus. The pandemic in the United States during 2020 was characterized by national ascertainment rates that increased from 11.3% (95% credible interval (CI): 8.3-15.9%) in March to 24.5% (18.6-32.3%) during December. Population susceptibility at the end of the year was 69.0% (63.6-75.4%), indicating that about one third of the US population had been infected. Community infectious rates, the percentage of people harbouring a contagious infection, increased above 0.8% (0.6-1.0%) before the end of the year, and were as high as 2.4% in some major metropolitan areas. By contrast, the infection fatality rate fell to 0.3% by year's end.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
Wu, J. T., Leung, K., & Leung, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30260-9 · Cited by 4,389
Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., & Shaman, J. (2020) · Science · doi:10.1126/science.abb3221 · Cited by 3,633
Self-citationPrevalence of Asymptomatic SARS-CoV-2 Infection
Oran, D. P., & Topol, E. J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-3012 · Cited by 2,348
Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility
Arons, M. M., Hatfield, K. M., Reddy, S. C., Kimball, A. A., James, A. E., Jacobs, J. R., Taylor, J., Spicer, K. B., Bardossy, A. C., Oakley, L. P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2008457 · Cited by 2,051
Age-specific mortality and immunity patterns of SARS-CoV-2
O’Driscoll, M., Ribeiro Dos Santos, G., Wang, L., Cummings, D. A. T., Azman, A. S., Paireau, J., Fontanet, A., Cauchemez, S., & Salje, H. (2021) · Nature · doi:10.1038/s41586-020-2918-0 · Cited by 1,210
Cited by
Sorted by citations
The Lancet Commission on lessons for the future from the COVID-19 pandemic
Sachs, J. D., Karim, S. S. A., Aknin, L., Allen, J., Brosbøl, K., Colombo, F., Barron, G. C., Espinosa, M. F., Gaspar, V., Gaviria, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01585-9 · Cited by 842
Human genetic and immunological determinants of critical COVID-19 pneumonia
Zhang, Q., Bastard, P., Effort, C. H. G., Karbuz, A., Gervais, A., Tayoun, A. N. A., Aiuti, A., Bélot, A., Bolze, A., Gaudet, A., et al. (2022) · Nature · doi:10.1038/s41586-022-04447-0 · Cited by 377
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
Manry, J., Bastard, P., Gervais, A., Voyer, T. L., Rosain, J., Philippot, Q., Michailidis, E., Hoffmann, H.-H., Eto, S., García-Prat, M., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200413119 · Cited by 205
Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis
Danwang, C., Noubiap, J. J., Robert, A. R., & Yombi, J. C. (2022) · AIDS Research and Therapy · doi:10.1186/s12981-021-00427-y · Cited by 155
Context-specific emergence and growth of the SARS-CoV-2 Delta variant
McCrone, J. T., Hill, V., Bajaj, S., Pena, R. E., Lambert, B. C., Inward, R. P. D., Bhatt, S., Volz, E., Ruis, C., Dellicour, S., et al. (2022) · Nature · doi:10.1038/s41586-022-05200-3 · Cited by 128
Metadata
- Authors
- Pei, S., Yamana, T. K., Kandula, S., Galanti, M., & Shaman, J.
- Affiliations
- Columbia University (US)
- Corresponding author
- Pei, Sen
- Shaman, Jeffrey
- Venue
- Nature
- Published
- 2021-08-26
- Volume
- 598
- Issue
- 7880
- Pages
- 338-341
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3195051481
- Cited by
- 190
- References
- 47
- Citations by year
- 2026: 6 · 2025: 20 · 2024: 31 · 2023: 58 · 2022: 64 · 2021: 11
- FWCI
- 15.92
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-12-17)
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nd)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Science Foundation (2027369)
- Mailman School of Public Health, Columbia University
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Applied Mathematics › Mathematical and Theoretical Epidemiology and Ecology Models
- Keywords
- COVID-19 pandemic, SARS-CoV-2, population susceptibility, infection fatality rate, disease transmission dynamics, human mobility, United States
- MeSH terms
- COVID-19, SARS-CoV-2, Calibration, Humans, United States, Incidence, Prevalence, Cost of Illness, Basic Reproduction Number, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
